TG Therapeutics To Present Real-World, Pediatric Study Design And Biomarker Data For BRIUMVI In Multiple Sclerosis At ACTRIMS Annual Forum

TG Therapeutics, Inc. +0.49%

TG Therapeutics, Inc.

TGTX

34.77

+0.49%

TG Therapeutics To Present Real-World, Pediatric Study Design And Biomarker Data For BRIUMVI In Multiple Sclerosis At ACTRIMS Annual Forum